Over the years, Ashok Leyland has done well to reduce its business cyclicality by focusing on non-MHCV segments. Further, a net cash position would help Ashok Leyand invest in growth avenues in the coming years.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Ashok Leyland Ltd.’s Q4 PAT at Rs 12.5 billion came in ahead of our estimate of Rs 10.8 billion, aided by better-than-expected operational performance (Ebitda margin at 15% ahead of our estimate of 14.2%) and higher other income.
Over the years, Ashok Leyland has done well to reduce its business cyclicality by focusing on non-MHCV segments. Further, a net cash position would help Ashok Leyand invest in growth avenues in the coming years.
Its focus on improving margins should bode well for returns in the long run. We reiterate our Buy rating with a target price of Rs 275 (based on 11x FY27E EV/Ebitda + ~Rs 19/share for the NBFC).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Ashok Leyland Lines Up Rs 5,000 Crore Investment To Localise Battery Ecosystem


Ashok Leyland Stock Q1 Review — Nirmal Bang Maintains 'Buy', Says Margins To Expand On Better Mix, Pricing


Ashok Leyland Q1 Results: Profit Up 13%, Margin Expands


Vodafone Idea, IOC, Ashok Leyland, Glenmark Pharma Q1 Results Today — Earnings Estimates
